NeuroMetrix Stock Surges As Its Nerve Stimulator Scores FDA Breakthrough Designation For Fibromyalgia

NeuroMetrix Inc's NURO Quell device has received Breakthrough Designation from the FDA to treat fibromyalgia symptoms in adults.
Fibromyalgia is a common form of chronic pain accompanied by fatigue, sleep, cognitive and mood disturbances.
Quell is a wearable electrical nerve stimulator. It utilizes position and motion sensing to automatically adjust stimulation for an optimal patient experience both day and night.
The data submitted by NeuroMetrix in support of the Breakthrough Designation included results of 119 subjects.
In an intention-to-treat (ITT) analysis of all subjects, 56% of those on active treatment exhibited a clinically meaningful improvement in health-related quality-of-life compared to 35% that received sham therapy.
The Company expects to launch Quell for fibromyalgia in the second half of 2022.
Price Action: NURO shares jump 43.9% at $4.69 during the market session on the last check Tuesday.
Related content: Benzinga's Full FDA Calendar.